Refine by
In Vivo Models Articles & Analysis
32 news found
Ace Therapeutics launches its cutting-edge in vivo models of diabetes mellitus. These models—chemically induced, genetically engineered, or diet-induced—have the potential to advance diabetes research by giving scientists the means to support the identification and development of novel treatment approaches. ...
These services encompass cell-level screening, identification of cell lines and models, genotyping services for rats and mice, PET-CT services, and flow cytometry services. ...
In light of the growing needs of customers for novel antiviral and antibacterial compounds to treat infectious diseases, Creative Diagnostics is leveraging its expertise to perform in vitro testing for compounds, thus, estimating their potential efficacies using in vivo models. If you have questions regarding the Microneutralization Assay Service or other In ...
Highlights: ES019 phagocytosis activity is corrected with PD-L1 level on tumor cells ES019 leads to better phagocytosis capability of tumor cells by M2-like than M1-like macrophage ES019 activates T cells without induction of phagocytosis of T cells ES019 shows favorable PK in mouse model ES019 demonstrates single agent anti-tumor efficacy in animal ...
Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s Identified two lead cannabinoid analog compounds for in vivo studies NSERC grant funding supports InMed’s collaborative research projects with Dr. ...
According to the classification of drugs and the characteristics of pharmacological effects, the efficacy and mechanism of drugs are reflected through appropriate in vitro and in vivo models, providing a basis for new drug development and supporting clinical research. ...
The data, including studies presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting & Pre-conference Programs in November 2021, has demonstrated that the combination of an ERK1/2 inhibitor and an immune checkpoint inhibitor (ICI) worked synergistically to produce improved efficacy in preclinical ICI-resistant in vivo mice models. ...
Confronting the growing demands for new antiviral and antimicrobial compounds as treatments for infectious diseases, Creative Diagnostics spares no effort to test these compounds in vitro to determine potential efficacy within in vivo models. If you need more information regarding the Fluorometric Neuraminidase Assay Service or have any questions related to the ...
The investigational product must be established to possess antiviral activity at concentrations achievable in vivo without causing toxic effects on cells. Furthermore, in cell culture models, the apparent antiviral activity of the investigational product may be the result of host cell death following exposure to the product. ...
The design incorporates microbiome biomarker data from human clinical data and nonclinical human cell-based assays and in vivo disease models. The SER-155 composition aims to decrease the colonization and translocation of antibiotic-resistant bacteria in the gastrointestinal tract to decrease the incidence of bloodstream infections and additionally to modulate ...
Exclusively in-licensed from UofL, compounds from this discovery engine have been shown to inhibit a broad range of RAS mutations and are active against the growth of multiple in vivo tumor models. Qualigen is evaluating promising compounds generated from this partnership in various RAS-driven advanced solid tumors such as pancreatic, colorectal and lung cancers. ...
Stephen Neidle Session Title: Structural and Chemical Biology Session Date and Time: Tuesday Apr 12, 2022 9:00 AM - 12:30 PM CDT Abstract Number: 4069 Title: “The potent quadruplex-binding compound SOP1812 shows anti-tumor activity in patient-derived in vivo models of pancreatic cancer” Lead Author: ...
INOVOTION’s high-value preclinical oncology assay quickly identifies your most effective anticancer drug candidates. Our unique technology guarantees fast, reliable, sensitive, and cost-effective results. And it will help you meet the 3Rs guidelines. Learn more and download one of our webinars! Take a step into the future of drug discovery!!! Let’s discover together how ...
Through this mechanism, QN-302 has demonstrated anti-tumor activity in multiple tumor types, including in-vivo PDAC models, without toxicity at proposed therapeutic doses. Further, studies suggest encouraging anti-tumor activity against gemcitabine-resistant tumors. ...
In preclinical proof-of-concept studies, IMA401 has shown anti-tumor activity with complete remissions in various in vivo tumor models including patient-derived xenograft models. The agreement outlines a development plan under which both companies will collaborate to advance the program through clinical development. ...
Individual antibodies against CHI3L1 or PD-1 had discrete antitumor effects and additive antitumor responses in metastasis models and T cell–tumor cell cocultures when administered simultaneously. Synergistic cytotoxic tumor cell death was seen in T cell–tumor cell cocultures, and significantly enhanced antitumor responses were seen in in vivo tumor ...
NK cells grown in NK-Xpander Medium exhibit a greater rate of expansion when compared to NK cells grown in other media and demonstrate cell killing in in vitro and in vivo models. In addition to their low immunogenicity, the ease of availability and sourcing of NK cells, coupled with efficient in vitro expansion, make them ideally suited for the development of ...
Data demonstrated tumor cell killing in vitro and complete regressions of established tumors in an in vivo tumor model. Immatics has selected a lead candidate for the clinical program and initiated manufacturing activities. ...
“EB003 demonstrated efficacy across multiple in vitro and in vivo models. Moreover, we observed significantly reduced STEC colonization and alleviated symptoms in 100% of treated animals in a disease model representative of the intended patient population. ...
Abologix has developed a new monoclonal antibody, code-named H225, that blocks the function of JAM-C. In preclinical in vivo animal models, Abologix has shown that treatment with H-225 significantly increases overall survival rates. ...
ByAbologix